Coya said the trial met its primary endpoint for safety and secondary endpoint for regulatory T cell (Treg) cell population enhancement, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement in 22 patients dosed with five days of LD IL-2 (106 IU/day) or placebo every four weeks for 21 weeks
Methylcobalamin B12 (525mcg, 21,875% DV) the bioactive form, not cyanocobalamin
Registry and cohort analyses from 2023-2025 suggest that GLP-1 therapies may be used in stable IBD without significantly increasing disease activity, though these studies have important limitations
A., Gottschalk, M., Kyllo, J
Additionally, dietary supplements in the United States are not regulated the same way as food products are